Every 10-Q that Rhythm Pharmaceuticals, Inc. (RYTM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RYTM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RYTM filings page.
Rhythm Pharmaceuticals, Inc. reported total revenues of $71.3 million for the quarter ended June 30 2026, all from IMCIVREE product sales, up from $48.5 million a year earlier. U.S. net product revenue was $51.0 million and international revenue was $20.3 million.
The company recorded a quarterly net loss of $49.3 million and a basic and diluted net loss per share of $0.73, with an accumulated deficit of $1.46 billion. As of June 30 2026, cash, cash equivalents and short‑term investments totaled $330.9 million, against a deferred royalty obligation of $106.1 million and Series A convertible preferred stock carrying value of $114.3 million. Management believes existing cash resources will be sufficient to fund operations for at least the next 24 months while it continues commercial expansion and development of its MC4R‑pathway pipeline.
Rhythm Pharmaceuticals reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Net product revenue rose to $60.1 million from $37.7 million, driven by IMCIVREE sales in the U.S. and internationally. Total revenue was $60.1 million after a prior-year license revenue reduction.
The company posted a net loss of $55.6 million, wider than $49.5 million a year earlier, with higher research and development and selling, general and administrative expenses. Cash, cash equivalents and short-term investments were $340.6 million, and management believes this will fund operations for at least the next 24 months. A deferred royalty obligation related to a royalty financing totaled $108.5 million, and Series A convertible preferred stock stood at $114.7 million. Common shares outstanding were 68.4 million as of March 31, 2026, with additional potential dilution from equity awards and convertible preferred stock.
Rhythm Pharmaceuticals (RYTM) filed its Q3 2025 10‑Q reporting higher sales and a narrower year‑to‑date loss. Q3 product revenue was $51.3 million, up from $33.3 million a year ago, reflecting continued uptake of IMCIVREE. The quarter’s net loss attributable to common stockholders was $54.3 million, or $0.82 per share.
For the nine months, revenue reached $132.5 million while the net loss narrowed to $149.0 million, helped by lower research and development expense ($125.3 million vs. $196.8 million in 2024) and higher selling, general and administrative expense supporting commercialization. Cash, cash equivalents and short‑term investments totaled $416.1 million as of September 30, 2025, with operating cash outflow of $90.3 million year‑to‑date. The company completed a public offering during the period, adding $188.7 million in net proceeds and also raised $34.0 million via an at‑the‑market program. Shares outstanding were 66,736,056 as of October 31, 2025.